Academic Journal
Effects of once‐weekly dulaglutide on kidney function in patients with type 2 diabetes in phase II and III clinical trials
| العنوان: | Effects of once‐weekly dulaglutide on kidney function in patients with type 2 diabetes in phase II and III clinical trials |
|---|---|
| المؤلفون: | Tuttle, Katherine R., McKinney, T. Dwight, Davidson, Jaime A., Anglin, Greg, Harper, Kristine D., Botros, Fady T. |
| المساهمون: | European Association for the Study of Diabetes, Merck Sharp and Dohme, Novo Nordisk, Amgen |
| المصدر: | Diabetes, Obesity and Metabolism ; volume 19, issue 3, page 436-441 ; ISSN 1462-8902 1463-1326 |
| بيانات النشر: | Wiley |
| سنة النشر: | 2016 |
| المجموعة: | Wiley Online Library (Open Access Articles via Crossref) |
| الوصف: | Dulaglutide is a once‐weekly glucagon‐like peptide‐1 receptor agonist approved for the treatment of type 2 diabetes (T2D). Integrated data from 9 phase II and III trials in people with T2D (N = 6005) were used to evaluate the effects of dulaglutide on estimated glomerular filtration rate ( eGFR [Chronic Kidney Disease Epidemiology Collaboration]), urine albumin‐to‐creatinine ratio ( UACR ) and kidney adverse events ( AEs ). No significant differences in eGFR were observed during treatment for dulaglutide vs placebo, active comparators or insulin glargine (mean ± standard deviation values: dulaglutide vs placebo: 87.8 ± 17.7 vs 88.2 ± 17.9 mL /min/1.73 m 2 , P = .075; dulaglutide vs active comparators: 89.9 ± 16.7 vs 88.8 ± 16.3 mL /min/1.73 m 2 , P = .223; and dulaglutide vs insulin glargine: 85.9 ± 18.2 vs 83.9 ± 18.6 mL /min/1.73 m 2 , P = .423). Lower UACR values were observed for dulaglutide vs placebo, active comparators and insulin glargine (at 26 weeks, median [ Q1‐Q3 ] values were: dulaglutide vs placebo: 8.0 [4.4‐20.4] vs 8.0 [4.4‐23.9] mg/g, P = .023; dulaglutide vs active comparators: 8.0 [4.4‐21.2] vs 8.9 [4.4‐27.4] mg/g, P = .013; and dulaglutide vs insulin glargine: 8.9 [4.4‐29.2] vs 12.4 [5.3‐50.5] mg/g, P = .029). AEs reflecting potential acute renal failure were 3.4, 1.7 and 7.0 events/1000 patient‐years for dulaglutide, active comparators and placebo, respectively. In conclusion, dulaglutide treatment of clinical trial participants with T2D did not affect eGFR and slightly decreased albuminuria. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| DOI: | 10.1111/dom.12816 |
| DOI: | 10.1111/dom.12816/fullpdf |
| الاتاحة: | http://dx.doi.org/10.1111/dom.12816 https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fdom.12816 http://onlinelibrary.wiley.com/wol1/doi/10.1111/dom.12816/fullpdf |
| Rights: | http://creativecommons.org/licenses/by-nc-nd/4.0/ |
| رقم الانضمام: | edsbas.86E9F2AD |
| قاعدة البيانات: | BASE |
| DOI: | 10.1111/dom.12816 |
|---|